IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Side Effects of Immune Checkpoint Inhibitors
March 21, 2017 | Online

Overview

With the integration of immunotherapy in the treatment of non-small cell lung cancer, recognition of potential side effects associated with immunotherapy and management of symptoms are essential components of overall care.

What you should expect to learn

After viewing this program, attendees will be able to:

  • Recognize the possible immune related toxicities during or after a patient receives immunotherapy.
  • Identify the possible immune related toxicities during or after a patient receives immunotherapy.
  • Distinguish how to counsel patients about what symptoms to relay to their health care team while receiving immunotherapy.

Julie R. Brahmer, M.D., M.Sc.

Director, Thoracic Oncology Program
Interim Director, 
Johns Hopkins Kimmel Cancer Center at Bayview
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, MD

&

Ramaswamy Govindan, MD - Program Chair

Co-Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Contact